In medicine, hemolytic-uremic syndrome (or haemolytic-uraemic syndrome, abbreviated HUS) is a disease characterised by microangiopathic hemolytic anemia, acute renal failure and a low platelet count (thrombocytopenia).
HUS occurs after 2-7% of all E. coli O157:H7 infections.
Adult HUS has similar symptoms and pathology but is an uncommon outcome of the following: HIV; antiphospholipid syndrome (associated with Lupus erythematosus and generalized hypercoagulability); post partum renal failure; malignant hypertension; scleroderma; and cancer chemotherapy (mitomycin, cyclosporine, cisplatin and bleomycin).
A third category is referred to as Familial HUS. It represents 5-10% of HUS cases and is due to an inheritied deficiency leading to uncontrolled complement system activation. Recurrent thromboses result in a high mortality rate.
HUS has a peak incidence between 6 months and 4 years of age (Corrigan and Boineau, 2001).
Clinically, HUS can be very hard to distinguish from thrombotic thrombocytopenic purpura (TTP). The laboratory features are almost identical, and not every case of HUS is preceded by diarrhea. The only distinguishing feature is that in TTP, neurological symptoms occur more often, but this is not always the case.
Often, plasmapheresis is also initiated, when there is diagnostic uncertainty between HUS and TTP.
This article is licensed under the GNU Free Documentation License.
It uses material from the
"Hemolytic-uremic syndrome".
Home Page • arts • business • computers • games • health • hospitals • home • kids & teens • news • physicians • recreation• reference • regional • science • shopping • society • sports • world